Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash & Equivalents (2016 - 2025)

CorMedix's Cash & Equivalents history spans 13 years, with the latest figure at $144.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 256.29% year-over-year to $144.8 million; the TTM value through Dec 2025 reached $144.8 million, up 256.29%, while the annual FY2025 figure was $144.8 million, 256.29% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $144.8 million at CorMedix, up from $48.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $159.3 million in Q2 2025 and bottomed at $19.7 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $45.4 million (2022), against an average of $56.9 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 524.48% in 2021 before it tumbled 69.02% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $53.3 million in 2021, then decreased by 19.07% to $43.1 million in 2022, then rose by 23.56% to $53.3 million in 2023, then decreased by 23.75% to $40.7 million in 2024, then soared by 256.29% to $144.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Cash & Equivalents are $144.8 million (Q4 2025), $48.5 million (Q3 2025), and $159.3 million (Q2 2025).